Oncology Biosimilars Market – Global Industry Analysis and Forecast 2026 – By Cancer Type, Product Type, Distribution Channel and Region.

Oncology Biosimilars Market – Global Industry Analysis and Forecast 2026 – By Cancer Type, Product Type, Distribution Channel and Region.

Market Scenario

Oncology Biosimilars Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at a XX% CAGR of around XX% during a forecast period. A biosimilar is a biologic drug that is similar to its reference drug, with no clinically meaningful differences in purity, potency, or safety; however, there may be some minor differences in its inactive components. Similarly, oncology biosimilar is the similar copy of oncology biologics used for the treatment of cancer. These oncology biosimilar is cost-effective, efficient, and have the identical ability as biologics. These molecules are easily produce as compared to biologics and it can only be manufactured after patent expiry. These are comparatively cheaper than branded or approved products. The scope of the report includes a detailed study of global and regional markets for Oncology Biosimilars with the reasons given for variants in the growth of the industry in certain regions. The oncology biosimilars market is anticipated to benefit enormously with the growing demand for reasonable therapies for cancer. ncreasing number of occurrences of for cancer such as cervical cancer, stomach cancer, lung cancer, and breast cancer is increasing demand for the appropriate treatment of every type of the caner is anticipated to drive the oncology biosimilars treatment market during forecast period. Recently, World Health Organization (WHO) reported that, around 8.8 million people died due to cancer in globe. Increasing frequency of several types of cancer across the globe is supporting the market growth. Increasing risk of cancer is related with increasing age, thus nearly 77% of all cancers are detected in elder population and most cases of cancer arise in middle-aged adults or older population. Considering this factors, the growth for the oncology biosimilars is anticipated to fuel by the expiration of the patents of a large number of biologics. These factors are also anticipated to contribute to the significant and fuel the growth of the oncology biosimilars market. Raising number of associations for development of biosimilar is anticipated to propel the growth of oncology biosimilars market during forecast period. Implementation of oncology biosimilars for the treatment of cancer is increasing growth of the oncology biosimilars market. Moreover, raising number of product approvals for treatment of several types of cancer is expected to drive the growth of market. Nevertheless, complex manufacturing process and its approval is key factor for hamper the growth oncology biosimilars market. The report on Oncology Biosimilars market covers segments such as By Cancer Type, Product Type, Distribution Channel and Region. The Cancer Type segment includes Lung Cancer, Colorectal cancer, Cervical Cancer, Breast Cancer, Kidney cancer, Stomach cancer, Brain Cancer, and Others. Among the Cancer Type, Breast cancer is anticipated to dominating segment throughout forecast period owing to raising incidence of breast cancer in globe. The Product Type segment is further sub-segmented into Monoclonal Antibody, Immunomodulators, Hematopoietic agents, G-CSF and Others. Among the product type, G-CSF is anticipated to hold major market share during forecast period due to raising demand of G-CSF for the treatment of breast cancer across the globe. Based on Distribution Channel, the Oncology Biosimilars market is sub-segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital Pharmacies occupied highest market share in 2018, due to the convenience of trained & qualified personnel and promising reimbursement structure. The online Pharmacies is projected to demonstration highest CAGR in the forecast period, which is recognized to the technological adaptation and acceptance of online Pharmacies by population. The retail Pharmacies demonstrated the reasonable market share in 2018 due to increasing geriatric population & developments in the healthcare amenities in emerging countries are estimated to drive the popularity of retail Pharmacies throughout the forecast period. Based on regional segment, the Oncology Biosimilars market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to hold the largest market share in the oncology biosimilar market throughout the forecast period. According to the American Society of Cancer (ASC), around 1.8 million new cases of cancer were registered and nearby 606,880 deaths from cancer are anticipated to occur in the US in 2019. Europe oncology biosimilar market is anticipated to increase significantly. Raising occurrence of breast cancer in the U.K and over 55,000 breast cancer cases are register each year in the U.K and about 4,700 in Scotland are the factors anticipated to drive the market growth in the region. Asia Pacific (APAC) is anticipated to the fastest developing oncology biosimilar market throughout the forecast period. Mostly, Breast cancer is commonly spread in Asian countries due to unhealthy lifestyle, increasing obesity which has increased demand of oncology biosimilar market. LAMEA is projected to grow at a steady rate due to the undeveloped healthcare amenities. Lack of awareness about the healthy lifestyle is reducing the cancer treatment in this region. Key players operating in the Oncology Biosimilars market Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., Biocon Limited., Celltrion Inc., Dr. Reddy’s Laboratories Ltd., STADA Arzneimittel AG, Intas Pharmaceuticals Ltd., Sandoz International GmbH, Apotex Inc., BIOCAD, Merck & Co., Inc., and Coherus Biosciences. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Oncology Biosimilars market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Oncology Biosimilars market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Scope of the Oncology Biosimilars Market

Oncology Biosimilars Market, By Cancer Type

• Lung Cancer • Colorectal cancer • Cervical Cancer • Breast Cancer • Kidney cancer • Stomach cancer • Brain Cancer • Others

Oncology Biosimilars Market, By Product Type

• Monoclonal Antibody • Immunomodulators • Hematopoietic agents • G-CSF • Others

Oncology Biosimilars Market, By Distribution Channel

• Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

Oncology Biosimilars Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Oncology Biosimilars Market

• Amgen Inc. • Allergan, Plc. • Mylan N.V. • Samsung Bioepis Co., Ltd. • Teva Pharmaceutical Industries Ltd. • Pfizer Inc. • Celltrion Healthcare • Novartis International AG • Biogen Idec, Inc. • Biocon Limited. • Celltrion Inc. • Dr. Reddy’s Laboratories Ltd. • STADA Arzneimittel AG • Intas Pharmaceuticals Ltd. • Sandoz International GmbH • Apotex Inc. • BIOCAD. • Merck & Co., Inc. • Coherus Biosciences

Table of Contents

Oncology Biosimilars Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Oncology Biosimilars Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Oncology Biosimilars Market Analysis and Forecast 6.1. Global Oncology Biosimilars Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Oncology Biosimilars Market Analysis and Forecast, By Cancer Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Oncology Biosimilars Market Value Share Analysis, By Cancer Type 7.4. Global Oncology Biosimilars Market Size (US$ Bn) Forecast, By Cancer Type 7.5. Global Oncology Biosimilars Market Analysis, By Cancer Type 7.6. Global Oncology Biosimilars Market Attractiveness Analysis, By Cancer Type 8. Oncology Biosimilars Market Analysis and Forecast, By Product Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Oncology Biosimilars Market Value Share Analysis, By Product Type 8.4. Global Oncology Biosimilars Market Size (US$ Bn) Forecast, By Product Type 8.5. Global Oncology Biosimilars Market Analysis, By Product Type 8.6. Global Oncology Biosimilars Market Attractiveness Analysis, By Product Type 9. Oncology Biosimilars Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Oncology Biosimilars Market Value Share Analysis, By Distribution Channel 9.4. Global Oncology Biosimilars Market Size (US$ Bn) Forecast, By Distribution Channel 9.5. Global Oncology Biosimilars Market Analysis, By Distribution Channel 9.6. Global Oncology Biosimilars Market Attractiveness Analysis, By Distribution Channel 10. Oncology Biosimilars Market Analysis, by Region 10.1. Global Oncology Biosimilars Market Value Share Analysis, by Region 10.2. Global Oncology Biosimilars Market Size (US$ Bn) Forecast, by Region 10.3. Global Oncology Biosimilars Market Attractiveness Analysis, by Region 11. North America Oncology Biosimilars Market Analysis 11.1. Key Findings 11.2. North America Oncology Biosimilars Market Overview 11.3. North America Oncology Biosimilars Market Value Share Analysis, By Cancer Type 11.4. North America Oncology Biosimilars Market Forecast, By Cancer Type 11.4.1. Lung Cancer 11.4.2. Colorectal cancer 11.4.3. Cervical Cancer 11.4.4. Breast Cancer 11.4.5. Kidney cancer 11.4.6. Stomach cancer 11.4.7. Brain Cancer 11.4.8. Others 11.5. North America Oncology Biosimilars Market Value Share Analysis, By Product Type 11.6. North America Oncology Biosimilars Market Forecast, By Product Type 11.6.1. Monoclonal Antibody 11.6.2. Immunomodulators 11.6.3. Hematopoietic agents 11.6.4. G-CSF 11.6.5. Others 11.7. North America Oncology Biosimilars Market Value Share Analysis, By Distribution Channel 11.8. North America Oncology Biosimilars Market Forecast, By Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Online Pharmacies 11.9. North America Oncology Biosimilars Market Value Share Analysis, by Country 11.10. North America Oncology Biosimilars Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Oncology Biosimilars Market Analysis, by Country 11.12. U.S. Oncology Biosimilars Market Forecast, By Cancer Type 11.12.1. Lung Cancer 11.12.2. Colorectal cancer 11.12.3. Cervical Cancer 11.12.4. Breast Cancer 11.12.5. Kidney cancer 11.12.6. Stomach cancer 11.12.7. Brain Cancer 11.12.8. Others 11.13. U.S. Oncology Biosimilars Market Forecast, By Product Type 11.13.1. Monoclonal Antibody 11.13.2. Immunomodulators 11.13.3. Hematopoietic agents 11.13.4. G-CSF 11.13.5. Others 11.14. U.S. Oncology Biosimilars Market Forecast, By Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Canada Oncology Biosimilars Market Forecast, By Cancer Type 11.15.1. Lung Cancer 11.15.2. Colorectal cancer 11.15.3. Cervical Cancer 11.15.4. Breast Cancer 11.15.5. Kidney cancer 11.15.6. Stomach cancer 11.15.7. Brain Cancer 11.15.8. Others 11.16. Canada Oncology Biosimilars Market Forecast, By Product Type 11.16.1. Monoclonal Antibody 11.16.2. Immunomodulators 11.16.3. Hematopoietic agents 11.16.4. G-CSF 11.16.5. Others 11.17. Canada Oncology Biosimilars Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Pharmacies 11.18. North America Oncology Biosimilars Market Attractiveness Analysis 11.18.1. By Cancer Type 11.18.2. By Product Type 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Oncology Biosimilars Market Analysis 12.1. Key Findings 12.2. Europe Oncology Biosimilars Market Overview 12.3. Europe Oncology Biosimilars Market Value Share Analysis, By Cancer Type 12.4. Europe Oncology Biosimilars Market Forecast, By Cancer Type 12.4.1. Lung Cancer 12.4.2. Colorectal cancer 12.4.3. Cervical Cancer 12.4.4. Breast Cancer 12.4.5. Kidney cancer 12.4.6. Stomach cancer 12.4.7. Brain Cancer 12.4.8. Others 12.5. Europe Oncology Biosimilars Market Value Share Analysis, By Product Type 12.6. Europe Oncology Biosimilars Market Forecast, By Product Type 12.6.1. Monoclonal Antibody 12.6.2. Immunomodulators 12.6.3. Hematopoietic agents 12.6.4. G-CSF 12.6.5. Others 12.7. Europe Oncology Biosimilars Market Value Share Analysis, By Distribution Channel 12.8. Europe Oncology Biosimilars Market Forecast, By Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Online Pharmacies 12.9. Europe Oncology Biosimilars Market Value Share Analysis, by Country 12.10. Europe Oncology Biosimilars Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Oncology Biosimilars Market Analysis, by Country 12.12. Germany Oncology Biosimilars Market Forecast, By Cancer Type 12.12.1. Lung Cancer 12.12.2. Colorectal cancer 12.12.3. Cervical Cancer 12.12.4. Breast Cancer 12.12.5. Kidney cancer 12.12.6. Stomach cancer 12.12.7. Brain Cancer 12.12.8. Others 12.13. Germany Oncology Biosimilars Market Forecast, By Product Type 12.13.1. Monoclonal Antibody 12.13.2. Immunomodulators 12.13.3. Hematopoietic agents 12.13.4. G-CSF 12.13.5. Others 12.14. Germany Oncology Biosimilars Market Forecast, By Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail Pharmacies 12.14.3. Online Pharmacies 12.15. U.K. Oncology Biosimilars Market Forecast, By Cancer Type 12.15.1. Lung Cancer 12.15.2. Colorectal cancer 12.15.3. Cervical Cancer 12.15.4. Breast Cancer 12.15.5. Kidney cancer 12.15.6. Stomach cancer 12.15.7. Brain Cancer 12.15.8. Others 12.16. U.K. Oncology Biosimilars Market Forecast, By Product Type 12.16.1. Monoclonal Antibody 12.16.2. Immunomodulators 12.16.3. Hematopoietic agents 12.16.4. G-CSF 12.16.5. Others 12.17. U.K. Oncology Biosimilars Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. France Oncology Biosimilars Market Forecast, By Cancer Type 12.18.1. Lung Cancer 12.18.2. Colorectal cancer 12.18.3. Cervical Cancer 12.18.4. Breast Cancer 12.18.5. Kidney cancer 12.18.6. Stomach cancer 12.18.7. Brain Cancer 12.18.8. Others 12.19. France Oncology Biosimilars Market Forecast, By Product Type 12.19.1. Monoclonal Antibody 12.19.2. Immunomodulators 12.19.3. Hematopoietic agents 12.19.4. G-CSF 12.19.5. Others 12.20. France Oncology Biosimilars Market Forecast, By Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail Pharmacies 12.20.3. Online Pharmacies 12.21. Italy Oncology Biosimilars Market Forecast, By Cancer Type 12.21.1. Lung Cancer 12.21.2. Colorectal cancer 12.21.3. Cervical Cancer 12.21.4. Breast Cancer 12.21.5. Kidney cancer 12.21.6. Stomach cancer 12.21.7. Brain Cancer 12.21.8. Others 12.22. Italy Oncology Biosimilars Market Forecast, By Product Type 12.22.1. Monoclonal Antibody 12.22.2. Immunomodulators 12.22.3. Hematopoietic agents 12.22.4. G-CSF 12.22.5. Others 12.23. Italy Oncology Biosimilars Market Forecast, By Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Online Pharmacies 12.24. Spain Oncology Biosimilars Market Forecast, By Cancer Type 12.24.1. Lung Cancer 12.24.2. Colorectal cancer 12.24.3. Cervical Cancer 12.24.4. Breast Cancer 12.24.5. Kidney cancer 12.24.6. Stomach cancer 12.24.7. Brain Cancer 12.24.8. Others 12.25. Spain Oncology Biosimilars Market Forecast, By Product Type 12.25.1. Monoclonal Antibody 12.25.2. Immunomodulators 12.25.3. Hematopoietic agents 12.25.4. G-CSF 12.25.5. Others 12.26. Spain Oncology Biosimilars Market Forecast, By Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail Pharmacies 12.26.3. Online Pharmacies 12.27. Rest of Europe Oncology Biosimilars Market Forecast, By Cancer Type 12.27.1. Lung Cancer 12.27.2. Colorectal cancer 12.27.3. Cervical Cancer 12.27.4. Breast Cancer 12.27.5. Kidney cancer 12.27.6. Stomach cancer 12.27.7. Brain Cancer 12.27.8. Others 12.28. Rest of Europe Oncology Biosimilars Market Forecast, By Product Type 12.28.1. Monoclonal Antibody 12.28.2. Immunomodulators 12.28.3. Hematopoietic agents 12.28.4. G-CSF 12.28.5. Others 12.29. Rest of Europe Oncology Biosimilars Market Forecast, By Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail Pharmacies 12.29.3. Online Pharmacies 12.30. Europe Oncology Biosimilars Market Attractiveness Analysis 12.30.1. By Cancer Type 12.30.2. By Product Type 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Oncology Biosimilars Market Analysis 13.1. Key Findings 13.2. Asia Pacific Oncology Biosimilars Market Overview 13.3. Asia Pacific Oncology Biosimilars Market Value Share Analysis, By Cancer Type 13.4. Asia Pacific Oncology Biosimilars Market Forecast, By Cancer Type 13.4.1. Lung Cancer 13.4.2. Colorectal cancer 13.4.3. Cervical Cancer 13.4.4. Breast Cancer 13.4.5. Kidney cancer 13.4.6. Stomach cancer 13.4.7. Brain Cancer 13.4.8. Others 13.5. Asia Pacific Oncology Biosimilars Market Value Share Analysis, By Product Type 13.6. Asia Pacific Oncology Biosimilars Market Forecast, By Product Type 13.6.1. Monoclonal Antibody 13.6.2. Immunomodulators 13.6.3. Hematopoietic agents 13.6.4. G-CSF 13.6.5. Others 13.7. Asia Pacific Oncology Biosimilars Market Value Share Analysis, By Distribution Channel 13.8. Asia Pacific Oncology Biosimilars Market Forecast, By Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Online Pharmacies 13.9. Asia Pacific Oncology Biosimilars Market Value Share Analysis, by Country 13.10. Asia Pacific Oncology Biosimilars Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Oncology Biosimilars Market Analysis, by Country 13.12. China Oncology Biosimilars Market Forecast, By Cancer Type 13.12.1. Lung Cancer 13.12.2. Colorectal cancer 13.12.3. Cervical Cancer 13.12.4. Breast Cancer 13.12.5. Kidney cancer 13.12.6. Stomach cancer 13.12.7. Brain Cancer 13.12.8. Others 13.13. China Oncology Biosimilars Market Forecast, By Product Type 13.13.1. Monoclonal Antibody 13.13.2. Immunomodulators 13.13.3. Hematopoietic agents 13.13.4. G-CSF 13.13.5. Others 13.14. China Oncology Biosimilars Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. India Oncology Biosimilars Market Forecast, By Cancer Type 13.15.1. Lung Cancer 13.15.2. Colorectal cancer 13.15.3. Cervical Cancer 13.15.4. Breast Cancer 13.15.5. Kidney cancer 13.15.6. Stomach cancer 13.15.7. Brain Cancer 13.15.8. Others 13.16. India Oncology Biosimilars Market Forecast, By Product Type 13.16.1. Monoclonal Antibody 13.16.2. Immunomodulators 13.16.3. Hematopoietic agents 13.16.4. G-CSF 13.16.5. Others 13.17. India Oncology Biosimilars Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Japan Oncology Biosimilars Market Forecast, By Cancer Type 13.18.1. Lung Cancer 13.18.2. Colorectal cancer 13.18.3. Cervical Cancer 13.18.4. Breast Cancer 13.18.5. Kidney cancer 13.18.6. Stomach cancer 13.18.7. Brain Cancer 13.18.8. Others 13.19. Japan Oncology Biosimilars Market Forecast, By Product Type 13.19.1. Monoclonal Antibody 13.19.2. Immunomodulators 13.19.3. Hematopoietic agents 13.19.4. G-CSF 13.19.5. Others 13.20. Japan Oncology Biosimilars Market Forecast, By Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Online Pharmacies 13.21. ASEAN Oncology Biosimilars Market Forecast, By Cancer Type 13.21.1. Lung Cancer 13.21.2. Colorectal cancer 13.21.3. Cervical Cancer 13.21.4. Breast Cancer 13.21.5. Kidney cancer 13.21.6. Stomach cancer 13.21.7. Brain Cancer 13.21.8. Others 13.22. ASEAN Oncology Biosimilars Market Forecast, By Product Type 13.22.1. Monoclonal Antibody 13.22.2. Immunomodulators 13.22.3. Hematopoietic agents 13.22.4. G-CSF 13.22.5. Others 13.23. ASEAN Oncology Biosimilars Market Forecast, By Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Online Pharmacies 13.24. Rest of Asia Pacific Oncology Biosimilars Market Forecast, By Cancer Type 13.24.1. Lung Cancer 13.24.2. Colorectal cancer 13.24.3. Cervical Cancer 13.24.4. Breast Cancer 13.24.5. Kidney cancer 13.24.6. Stomach cancer 13.24.7. Brain Cancer 13.24.8. Others 13.25. Rest of Asia Pacific Oncology Biosimilars Market Forecast, By Product Type 13.25.1. Monoclonal Antibody 13.25.2. Immunomodulators 13.25.3. Hematopoietic agents 13.25.4. G-CSF 13.25.5. Others 13.26. Rest of Asia Pacific Oncology Biosimilars Market Forecast, By Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Online Pharmacies 13.27. Asia Pacific Oncology Biosimilars Market Attractiveness Analysis 13.27.1. By Cancer Type 13.27.2. By Product Type 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Oncology Biosimilars Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Oncology Biosimilars Market Overview 14.3. Middle East & Africa Oncology Biosimilars Market Value Share Analysis, By Cancer Type 14.4. Middle East & Africa Oncology Biosimilars Market Forecast, By Cancer Type 14.4.1. Lung Cancer 14.4.2. Colorectal cancer 14.4.3. Cervical Cancer 14.4.4. Breast Cancer 14.4.5. Kidney cancer 14.4.6. Stomach cancer 14.4.7. Brain Cancer 14.4.8. Others 14.5. Middle East & Africa Oncology Biosimilars Market Value Share Analysis, By Product Type 14.6. Middle East & Africa Oncology Biosimilars Market Forecast, By Product Type 14.6.1. Monoclonal Antibody 14.6.2. Immunomodulators 14.6.3. Hematopoietic agents 14.6.4. G-CSF 14.6.5. Others 14.7. Middle East & Africa Oncology Biosimilars Market Value Share Analysis, By Distribution Channel 14.8. Middle East & Africa Oncology Biosimilars Market Forecast, By Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Online Pharmacies 14.9. Middle East & Africa Oncology Biosimilars Market Value Share Analysis, by Country 14.10. Middle East & Africa Oncology Biosimilars Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Oncology Biosimilars Market Analysis, by Country 14.12. GCC Oncology Biosimilars Market Forecast, By Cancer Type 14.12.1. Lung Cancer 14.12.2. Colorectal cancer 14.12.3. Cervical Cancer 14.12.4. Breast Cancer 14.12.5. Kidney cancer 14.12.6. Stomach cancer 14.12.7. Brain Cancer 14.12.8. Others 14.13. GCC Oncology Biosimilars Market Forecast, By Product Type 14.13.1. Monoclonal Antibody 14.13.2. Immunomodulators 14.13.3. Hematopoietic agents 14.13.4. G-CSF 14.13.5. Others 14.14. GCC Oncology Biosimilars Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Online Pharmacies 14.15. South Africa Oncology Biosimilars Market Forecast, By Cancer Type 14.15.1. Lung Cancer 14.15.2. Colorectal cancer 14.15.3. Cervical Cancer 14.15.4. Breast Cancer 14.15.5. Kidney cancer 14.15.6. Stomach cancer 14.15.7. Brain Cancer 14.15.8. Others 14.16. South Africa Oncology Biosimilars Market Forecast, By Product Type 14.16.1. Monoclonal Antibody 14.16.2. Immunomodulators 14.16.3. Hematopoietic agents 14.16.4. G-CSF 14.16.5. Others 14.17. South Africa Oncology Biosimilars Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. Rest of Middle East & Africa Oncology Biosimilars Market Forecast, By Cancer Type 14.18.1. Lung Cancer 14.18.2. Colorectal cancer 14.18.3. Cervical Cancer 14.18.4. Breast Cancer 14.18.5. Kidney cancer 14.18.6. Stomach cancer 14.18.7. Brain Cancer 14.18.8. Others 14.19. Rest of Middle East & Africa Oncology Biosimilars Market Forecast, By Product Type 14.19.1. Monoclonal Antibody 14.19.2. Immunomodulators 14.19.3. Hematopoietic agents 14.19.4. G-CSF 14.19.5. Others 14.20. Rest of Middle East & Africa Oncology Biosimilars Market Forecast, By Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Online Pharmacies 14.21. Middle East & Africa Oncology Biosimilars Market Attractiveness Analysis 14.21.1. By Cancer Type 14.21.2. By Product Type 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Oncology Biosimilars Market Analysis 15.1. Key Findings 15.2. South America Oncology Biosimilars Market Overview 15.3. South America Oncology Biosimilars Market Value Share Analysis, By Cancer Type 15.4. South America Oncology Biosimilars Market Forecast, By Cancer Type 15.4.1. Lung Cancer 15.4.2. Colorectal cancer 15.4.3. Cervical Cancer 15.4.4. Breast Cancer 15.4.5. Kidney cancer 15.4.6. Stomach cancer 15.4.7. Brain Cancer 15.4.8. Others 15.5. South America Oncology Biosimilars Market Value Share Analysis, By Product Type 15.6. South America Oncology Biosimilars Market Forecast, By Product Type 15.6.1. Monoclonal Antibody 15.6.2. Immunomodulators 15.6.3. Hematopoietic agents 15.6.4. G-CSF 15.6.5. Others 15.7. South America Oncology Biosimilars Market Value Share Analysis, By Distribution Channel 15.8. South America Oncology Biosimilars Market Forecast, By Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Online Pharmacies 15.9. South America Oncology Biosimilars Market Value Share Analysis, by Country 15.10. South America Oncology Biosimilars Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Oncology Biosimilars Market Analysis, by Country 15.12. Brazil Oncology Biosimilars Market Forecast, By Cancer Type 15.12.1. Lung Cancer 15.12.2. Colorectal cancer 15.12.3. Cervical Cancer 15.12.4. Breast Cancer 15.12.5. Kidney cancer 15.12.6. Stomach cancer 15.12.7. Brain Cancer 15.12.8. Others 15.13. Brazil Oncology Biosimilars Market Forecast, By Product Type 15.13.1. Monoclonal Antibody 15.13.2. Immunomodulators 15.13.3. Hematopoietic agents 15.13.4. G-CSF 15.13.5. Others 15.14. Brazil Oncology Biosimilars Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Online Pharmacies 15.15. Mexico Oncology Biosimilars Market Forecast, By Cancer Type 15.15.1. Lung Cancer 15.15.2. Colorectal cancer 15.15.3. Cervical Cancer 15.15.4. Breast Cancer 15.15.5. Kidney cancer 15.15.6. Stomach cancer 15.15.7. Brain Cancer 15.15.8. Others 15.16. Mexico Oncology Biosimilars Market Forecast, By Product Type 15.16.1. Monoclonal Antibody 15.16.2. Immunomodulators 15.16.3. Hematopoietic agents 15.16.4. G-CSF 15.16.5. Others 15.17. Mexico Oncology Biosimilars Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. Rest of South America Oncology Biosimilars Market Forecast, By Cancer Type 15.18.1. Lung Cancer 15.18.2. Colorectal cancer 15.18.3. Cervical Cancer 15.18.4. Breast Cancer 15.18.5. Kidney cancer 15.18.6. Stomach cancer 15.18.7. Brain Cancer 15.18.8. Others 15.19. Rest of South America Oncology Biosimilars Market Forecast, By Product Type 15.19.1. Monoclonal Antibody 15.19.2. Immunomodulators 15.19.3. Hematopoietic agents 15.19.4. G-CSF 15.19.5. Others 15.20. Rest of South America Oncology Biosimilars Market Forecast, By Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Online Pharmacies 15.21. South America Oncology Biosimilars Market Attractiveness Analysis 15.21.1. By Cancer Type 15.21.2. By Product Type 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Product Types and R&D investment 16.2.2. New Treatment Center Launches and Treatment Center Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Product Types 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Amgen Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Treatment Center Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Allergan, Plc. 16.3.3. Mylan N.V. 16.3.4. Samsung Bioepis Co., Ltd. 16.3.5. Teva Pharmaceutical Industries Ltd. 16.3.6. Pfizer Inc. 16.3.7. Celltrion Healthcare 16.3.8. Novartis International AG 16.3.9. Biogen Idec, Inc. 16.3.10. Biocon Limited. 16.3.11. Celltrion Inc. 16.3.12. Dr. Reddy’s Laboratories Ltd. 16.3.13. STADA Arzneimittel AG 16.3.14. Intas Pharmaceuticals Ltd. 16.3.15. Sandoz International GmbH 16.3.16. Apotex Inc. 16.3.17. BIOCAD. 16.3.18. Merck & Co., Inc. 16.3.19. Coherus Biosciences 17. Primary Key Insights

About This Report

Report ID39767
Category Healthcare
Published DateDec 2019
No of Pages185
Contact Us